Optimizing treatment of diabetes and cardiovascular disease with combined α,β‐blockade

References

• Dornhorst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet 1985;1:123–6
   Google Scholar
• Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955–9
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol–metoprolol study. J Hypertens 1996;14:489–94
   PubMed Web of Science ®Google Scholar
• Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003;146:848–53
   PubMed Web of Science ®Google Scholar
• Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The national health and nutrition examination surveys, 1960 to 1991. J Am Med Assoc 1994;272: 205–11
   Google Scholar
• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979;241:2035–8
   PubMed Web of Science ®Google Scholar
• Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care 2002;25: 1410–7
   Google Scholar
• Celentano A, Vaccaro O, Tammaro P, et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol 1995;76:1173–6
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities study. New Engl J Med 2000;342: 905–12
   Google Scholar
• Harris MI. Epidemiology of diabetes mellitus among the elderly in the United States. Clin Geriatr Med 1990;6:703–19
   PubMedGoogle Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339: 229–34
   Google Scholar
• Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. Br Med J 2002;324: 939
   Google Scholar
• Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. J Am Med Assoc 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure]. J Am Coll Cardiol 2001;38: 2101–13
   Google Scholar
• Bloomgarden ZT. Obesity, hypertension, and insulin resistance. Diabetes Care 2002;25:2088–97
   PubMed Web of Science ®Google Scholar
• Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. New Engl J Med 2004;350: 664–71
   Google Scholar
• Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated redof genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003;100:8466–71
   PubMed Web of Science ®Google Scholar
• Zavaroni I, Mazza S, Dall’Aglio E, et al. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992;231:235–40
   Google Scholar
• Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997;30:527–32
   PubMed Web of Science ®Google Scholar
• Bell DS. Diabetic cardiomyopathy. Diabetes Care 2003;26: 2949–51
   PubMed Web of Science ®Google Scholar
• Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New Engl J Med 1984;311:819–23
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983;5:86–99
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998;11:1258–65
   Google Scholar
• Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998;41:39–52
   PubMed Web of Science ®Google Scholar
• Coats AJ, Anker SD, Anker S. Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol 2000;35:S9–S14
   Google Scholar
• Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New Engl J Med 1988;318:1315–21
   Google Scholar
• Bell DSH. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 1995;18:708–14
   Google Scholar
• Ziegelhoffer A, Ravingerova T, Styk J, et al. Mechanisms that may be involved in calcium tolerance of the diabetic heart. Mol Cell Biochem 1997;176:191–8
   PubMed Web of Science ®Google Scholar
• Wakasaki H, Koya D, Schoen FJ, et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 1997;94:9320–5
   PubMed Web of Science ®Google Scholar
• Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect 2002;15:197–205
   PubMed Web of Science ®Google Scholar
• Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation 2002;105:1861–70
   Google Scholar
• Stahl A, Evans JG, Pattel S, Hirsch D, Lodish HF. Insulin causes fatty acid transport protein translocation and enhanced fatty acid uptake in adipocytes. Dev Cell 2002;2:477–88
   Google Scholar
• Meijssen S, Cabezas MC, Ballieux CG, et al. Insulin mediated inhibition of hormone sensitive lipase activity in vivo in relation to endogenous catecholamines in healthy subjects. J Clin Endocrinol Metab 2001;86:4193–7
   PubMed Web of Science ®Google Scholar
• Morimoto C, Tsujita T, Okuda H. Norepinephrine-induced lipolysis in rat fat cells from visceral and subcutaneous sites: role of hormone-sensitive lipase and lipid droplets. J Lipid Res 1997;38:132–8
   Google Scholar
• Rabkin SW. Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 1993;33:286–91
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–607
   PubMed Web of Science ®Google Scholar
• Ridker PM, Genest J, Libby P. Risk factors for atherosclerotic disease. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease: a textbook of cardiovascular medicine. Philadelphia: Saunders; 2001. p. 1010–40
   Google Scholar
• Shen GX, Cai W, Angel A. Increased secretion of cholesteryl ester transfer protein from hamster adipose tissue: stimulation by beta-adrenergic agents. Atherosclerosis 1998;140:113–20
   Google Scholar
• Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993;102:63–7
   Google Scholar
• Knott HM, Brown BE, Davies MJ, Dean RT. Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles. Eur J Biochem 2003;270:3572–82
   PubMedGoogle Scholar
• Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155–8
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. J Am Med Assoc 2003;289:2560–72
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751–6
   PubMed Web of Science ®Google Scholar
• Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Committee on Management of Acute Myocardial Infarction]. Circulation 1999;100:1016–30
   Google Scholar
• Smith Jr SC, Blair SN, Bonow RO, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577–9
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13
   PubMed Web of Science ®Google Scholar
• MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–7
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. New Engl J Med 2001;344:1651–8
   PubMed Web of Science ®Google Scholar
• Tse WY, Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med 1994;11:137–44
   PubMed Web of Science ®Google Scholar
• Bell DS. Advantages of a third-generation beta-blocker in patients with diabetes mellitus. Am J Cardiol 2004;93:49–52
   PubMedGoogle Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998;317: 713–20
   Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial [HOT Study Group]. Lancet 1998;351:1755–62
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43–50
   PubMed Web of Science ®Google Scholar
• Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285–90
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. New Engl J Med 1998;339:489–97
   Google Scholar
• Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease [Bezafibrate Infarction Prevention (BIP) Study Group]. Am J Cardiol 1996;77:1273–7
   PubMedGoogle Scholar
• Fonarow GC. The acute decompensated heart failure national registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(Suppl 7):S21–S30
   Google Scholar
• Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529–38
   PubMed Web of Science ®Google Scholar
• Rocha RM, Silva GV, Perin EC, et al. Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly? Tex Heart Inst J 2003;30: 176–9
   PubMed Web of Science ®Google Scholar
• Mohacsi P, Fowler MB, Krum H, et al. Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study. Presented at the American Heart Association 74th Annual scientific Session; November 14, 2001; Anaheim, CA [abstract 3551]. Circulation 2001;104(Suppl II):II–754
   Google Scholar
• Bristow MR. Effect of carvedilol on LV function and mortality in diabetic vs non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. Presented at the 69th Scientific Sessions, New Orleans Convention Center; November 10–13, 1996; New Orleans, LA. Circulation 1996;84: I–644
   Google Scholar
• Fonarow GC. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med 2004;116(Suppl 5A):76S–88S
   Google Scholar
• Black HR. Metabolic considerations in the choice of therapy for the patient with hypertension. Am Heart J 1991;121:707–15
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335: 827–38
   Google Scholar
• Barzilay JI, Pressel S, Davis BR, et al. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ACE inhibitor, a diuretic, or a calcium channel blocker: a report from the ALLHAT trial. Am J Hypertens 2004;17:S1
   Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002;288:2981–97
   Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002;20:1879–86
   Google Scholar
• Olsen MH, Fossum E, Hoieggen A, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005;23:891–8
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Cleland JG, Metra M, et al. Effect of long-term treatment with carvedilol compared to metoprolol on heart failure morbidity and diabetes in COMET. Presented at the American College of Cardiology (ACC) 53rd Annual Scientific Sessions; March 7–10, 2004; New Orleans, LA; Tracking number – 04-A-294565-ACC . J Am Coll Cardiol 2004;43
   Google Scholar
• Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system. New Engl J Med 1996;334:374–81
   Google Scholar
• Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New Engl J Med 1981;304:801–7
   PubMed Web of Science ®Google Scholar
• Weinberger MH. Antihypertensive therapy and lipids. Evidence, mechanisms, and implications. Arch Intern Med 1985;145:1102–5
   PubMed Web of Science ®Google Scholar
• Osmundson PJ, O’Fallon WM, Zimmerman BR, et al. Course of peripheral occlusive arterial disease in diabetes. Vascular laboratory assessment. Diabetes Care 1990;13:143–52
   PubMed Web of Science ®Google Scholar
• Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;2:650–3
   PubMed Web of Science ®Google Scholar
• Schaper NC, Nabuurs-Franssen MH, Huijberts MS. Peripheral vascular disease and type 2 diabetes mellitus. Diabetes Metab Res Rev 2000;16(Suppl 1):S11–S15
   Google Scholar
• International Working Group on the Diabetic Foot. Peripheral vascular disease. In: Apelqvist J, Bakker K, van Houtum WH, Nabuurs-Franssen MH, Schaper NC, editors. International consensus on the diabetic foot. Maastricht: International Diabetes Federation; 1999. p. 33–41
   Google Scholar
• Beach KW, Bedford GR, Bergelin RO, et al. Progression of lower-extremity arterial occlusive disease in type II diabetes mellitus. Diabetes Care 1988;11:464–72
   PubMed Web of Science ®Google Scholar
• Popp DA, Tse TF, Shah SD, Clutter WE, Cryer PE. Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. Diabetes Care 1984;7:243–7
   Google Scholar
• Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. J Am Med Assoc 1997;278:40–3
   PubMed Web of Science ®Google Scholar
• Deacon SP, Karunanayake A, Barnett D. Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Br Med J 1977;2:1255–7
   Google Scholar
• Bell DSH, Yumuk V. Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin. Endocr Pract 1997;3:281–3
   PubMedGoogle Scholar
• Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989;198:1152–7
   Google Scholar
• Samuelsson O, Hedner T, Berglund G, et al. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens 1994;8:257–63
   PubMed Web of Science ®Google Scholar
• Leren P, Foss PO, Helgeland A, et al. Effect of propranolol and prazosin on blood lipids [The Oslo Study]. Lancet 1980;2:4–6
   PubMed Web of Science ®Google Scholar
• Haenni A, Lithell H. Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994;43:455–61
   PubMed Web of Science ®Google Scholar
• FDA Working Group, Pharmaceutical Research Manufacturers of America, American Association for the Study of Liver Diseases. Clinical white paper. Prepared for the conference, drug-induced liver injury: a national and global problem, 12–13 February 2001, Westfields Conference Center, Chantilly, VA. 2000
   Google Scholar
• Malminiemi K. Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Ther 1995;9:295–304
   PubMed Web of Science ®Google Scholar
• Flamenbaum W, Weber MA, McMahon FG, et al. Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens 1985;1:56–69
   PubMedGoogle Scholar
• Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. J Am Med Assoc 2004;292:2227–36
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405–12
   PubMed Web of Science ®Google Scholar
• Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC- Norfolk). Br Med J 2001;322:15–8
   PubMed Web of Science ®Google Scholar
• Barzilay JI, Peterson D, Cushman M, et al. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis 2004;44:25–34
   PubMed Web of Science ®Google Scholar
• Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19:1992–7
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001;286:421–6
   PubMed Web of Science ®Google Scholar
• Messerli F, Bakris G, Bell D, et al. Weight change and insulin sensitivity – not all beta-blockers are created equal. Presented at: American Society of Hypertension 20th Annual Scientific Meeting and Exposition; May 14–18 2005; San Francisco, CA
   Google Scholar